154 related articles for article (PubMed ID: 17309600)
1. Immunohistochemical expression of the beta-catenin-interacting protein B9L is associated with histological high nuclear grade and immunohistochemical ErbB2/HER-2 expression in breast cancers.
Toya H; Oyama T; Ohwada S; Togo N; Sakamoto I; Horiguchi J; Koibuchi Y; Adachi S; Jigami T; Nakajima T; Akiyama T
Cancer Sci; 2007 Apr; 98(4):484-90. PubMed ID: 17309600
[TBL] [Abstract][Full Text] [Related]
2. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
3. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of a BCL9-related beta-catenin-binding protein, B9L, in different stages of sporadic colorectal adenoma.
Sakamoto I; Ohwada S; Toya H; Togo N; Kashiwabara K; Oyama T; Nakajima T; Ito H; Adachi S; Jigami T; Akiyama T
Cancer Sci; 2007 Jan; 98(1):83-7. PubMed ID: 17129358
[TBL] [Abstract][Full Text] [Related]
5. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
Hanley K; Wang J; Bourne P; Yang Q; Gao AC; Lyman G; Tang P
Hum Pathol; 2008 Mar; 39(3):386-92. PubMed ID: 18187183
[TBL] [Abstract][Full Text] [Related]
6. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Bircan S; Kapucuoglu N; Baspinar S; Inan G; Candir O
Pathol Res Pract; 2006; 202(8):569-76. PubMed ID: 16828238
[TBL] [Abstract][Full Text] [Related]
7. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
Tezel GG; Uner A; Yildiz I; Guler G; Takahashi M
Pathol Res Pract; 2009; 205(6):403-8. PubMed ID: 19232840
[TBL] [Abstract][Full Text] [Related]
8. Wnt pathway component LEF1 mediates tumor cell invasion and is expressed in human and murine breast cancers lacking ErbB2 (her-2/neu) overexpression.
Nguyen A; Rosner A; Milovanovic T; Hope C; Planutis K; Saha B; Chaiwun B; Lin F; Imam SA; Marsh JL; Holcombe RF
Int J Oncol; 2005 Oct; 27(4):949-56. PubMed ID: 16142310
[TBL] [Abstract][Full Text] [Related]
9. E2F-1: a proliferative marker of breast neoplasia.
Zhang SY; Liu SC; Al-Saleem LF; Holloran D; Babb J; Guo X; Klein-Szanto AJ
Cancer Epidemiol Biomarkers Prev; 2000 Apr; 9(4):395-401. PubMed ID: 10794484
[TBL] [Abstract][Full Text] [Related]
10. Stromal CD10 expression and relationship to the E-cadherin/beta-catenin complex in breast carcinoma.
Kim HS; Kim GY; Kim YW; Park YK; Song JY; Lim SJ
Histopathology; 2010 May; 56(6):708-19. PubMed ID: 20546336
[TBL] [Abstract][Full Text] [Related]
11. C-KIT expression in ductal carcinoma in situ of the breast: co-expression with HER-2/neu.
Diallo R; Rody A; Jackisch C; Ting E; Schaefer KL; Kissler S; Karn T; Geddert H; Engels K; Kaufmann M; Gabbert HE; Shroyer KR; Poremba C
Hum Pathol; 2006 Feb; 37(2):205-11. PubMed ID: 16426921
[TBL] [Abstract][Full Text] [Related]
12. Immunolocalization of liver receptor homologue-1 (LRH-1) in human breast carcinoma: possible regulator of insitu steroidogenesis.
Miki Y; Clyne CD; Suzuki T; Moriya T; Shibuya R; Nakamura Y; Ishida T; Yabuki N; Kitada K; Hayashi S; Sasano H
Cancer Lett; 2006 Nov; 244(1):24-33. PubMed ID: 16427184
[TBL] [Abstract][Full Text] [Related]
13. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.
Gonzalez LO; Corte MD; Junquera S; Bongera M; Rodriguez JC; Vizoso FJ
Histopathology; 2007 Jun; 50(7):866-74. PubMed ID: 17543076
[TBL] [Abstract][Full Text] [Related]
14. Caveolin-1 is down-regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast.
Park SS; Kim JE; Kim YA; Kim YC; Kim SW
Histopathology; 2005 Dec; 47(6):625-30. PubMed ID: 16324201
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical co-expression of c-erbb-2/Neu oncoprotein, altered tumour suppressor (p53) protein, EGF-R and EMA in histological subtypes of infiltrating duct carcinoma of the breast.
Sharma BK; Ray A; Kaur S; Gupta S
Indian J Exp Biol; 1999 Mar; 37(3):223-7. PubMed ID: 10641149
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical analysis of p53 expression in primary breast carcinomas.
Naidu R; Yadav M; Nair S; Kutty KK
Anticancer Res; 1998; 18(1A):65-70. PubMed ID: 9568057
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome.
Vestey SB; Perks CM; Sen C; Calder CJ; Holly JM; Winters ZE
Breast Cancer Res; 2005; 7(1):R119-29. PubMed ID: 15642160
[TBL] [Abstract][Full Text] [Related]
18. Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients.
López-Knowles E; Zardawi SJ; McNeil CM; Millar EK; Crea P; Musgrove EA; Sutherland RL; O'Toole SA
Cancer Epidemiol Biomarkers Prev; 2010 Jan; 19(1):301-9. PubMed ID: 20056651
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast.
Shibuya R; Suzuki T; Miki Y; Yoshida K; Moriya T; Ono K; Akahira J; Ishida T; Hirakawa H; Evans DB; Sasano H
Endocr Relat Cancer; 2008 Mar; 15(1):113-24. PubMed ID: 18310280
[TBL] [Abstract][Full Text] [Related]
20. Concomitant expression of epithelial-mesenchymal transition biomarkers in breast ductal carcinoma: association with progression.
Logullo AF; Nonogaki S; Pasini FS; Osório CA; Soares FA; Brentani MM
Oncol Rep; 2010 Feb; 23(2):313-20. PubMed ID: 20043090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
